de Bakker, Marie
Petersen, Teun B.
Akkerhuis, K. Martijn
Harakalova, Magdalena
Umans, Victor A.
Germans, Tjeerd
Caliskan, Kadir
Katsikis, Peter D.
van der Spek, Peter J.
Suthahar, Navin
de Boer, Rudolf A.
Rizopoulos, Dimitris
Asselbergs, Folkert W.
Boersma, Eric
Kardys, Isabella http://orcid.org/0000-0002-2115-9745
Funding for this research was provided by:
EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking BigData@Heart grant (116074)
Jaap Schouten Foundation
Noordwest Academie
Article History
Received: 24 February 2023
Accepted: 5 May 2023
First Online: 17 May 2023
Declarations
:
: The medical ethics committee of the Erasmus Medical Center in Rotterdam approved the study protocol (MEC-2011-029), and all patients provided written informed consent. The study was conducted in accordance with the declaration of Helsinki and registered in ClinicalTrial.gov (NCT01851538).
: Not applicable.
: Dr. De Boer has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche; and has had speaker engagements with Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, and Roche.